08/01/2024Published by Fondazione Gianni Bonadonna at 08/01/2024Categories Events UncategorizedInavosilib in HR+/HER2- locally advanced or metastatic breast cancer
18/12/2023Published by Fondazione Gianni Bonadonna at 18/12/2023Categories Events UncategorizedPatritumab deruxtecan in HER-3 expressing metastatic breast cancer
11/12/2023Published by Fondazione Gianni Bonadonna at 11/12/2023Categories Events UncategorizedBenefits with nimotuzumab plus gemcitabine in K-Ras wild-type pancreatic cancer
04/12/2023Published by Fondazione Gianni Bonadonna at 04/12/2023Categories Events UncategorizedDivarasib in solid tumors with a KRAS G12C mutation
27/11/2023Published by Fondazione Gianni Bonadonna at 27/11/2023Categories Events UncategorizedOral SERDs in ER+/HER2- metastatic breast cancer, an analysis of ESR1 wild type/mutant subgroups
20/11/2023Published by Fondazione Gianni Bonadonna at 20/11/2023Categories Events UncategorizedPembrolizumab plus enfortumab vedotin in bladder cancer
13/11/2023Published by Fondazione Gianni Bonadonna at 13/11/2023Categories Events UncategorizedMolecular features of high proliferation/low ER-related signaling breast cancers suggest more effective therapeutic strategies
06/11/2023Published by Fondazione Gianni Bonadonna at 06/11/2023Categories Events UncategorizedClinical outcomes of luminal-like breast cancers with estrogen receptors loss at metastatic relapse
30/10/2023Published by Fondazione Gianni Bonadonna at 30/10/2023Categories Events UncategorizedSacituzumab govitecan in ER+/HER2- metastatic breast cancer
